Treatment of cholangiocarcinoma cell lines with PI3K inhibitor (LY294002) or the MEK 1/2 (UO126) attenuated the effect of CXCL12-induced cholangiocarcinoma cell invasion. The gene discussed is MAP2K1; the disease is cholangiocarcinoma.